If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ® (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Why is the Omvoh® (mirikizumab-mrkz) Crohn's disease maintenance dose 2 injections?
In the mirikizumab Crohn's disease clinical development program, participants received a full maintenance dose through one 2-mL injection and one 1-mL injection. The efficacy of a single 3-mL injection has not been evaluated.
Maintenance Dosage and Administration of Mirikizumab for Crohn's Disease
The recommended maintenance dosage of mirikizumab for the treatment of Crohn's disease is 300 mg administered by subcutaneous injection, given as 2 consecutive injections of 100 mg and 200 mg, at week 12, and every 4 weeks thereafter.1
Mirikizumab for the treatment of Crohn's disease is available for subcutaneous injection as 200 mg/2 mL plus 100 mg/mL solution in a single-dose prefilled pen, or as 200 mg/2 mL (100 mg/mL) plus 100 mg/mL solution in a single-dose prefilled syringe.1
Enclosed Prescribing Information
Reference
1Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: January 15, 2025